Novel therapeutic combinations including the concomitant use of PARP inhibitors (KEYLYNK-013) or anti-TIGIT monoclonal antibodies (AdvanTIG-204, ML41257) are being actively investigated with immunotherapy in LS-SCLC [37, 41, 51]. This evidence concerns the gene TIGIT and small cell lung carcinoma.